Merck (MRK) Deferred Taxes (2009 - 2026)
Merck (MRK) reported Deferred Taxes of -$315.0 million for Q1 2026, down 69.35% year-over-year from -$1.0 billion in Q1 2025, and up 61.82% quarter-over-quarter from -$825.0 million in Q4 2025.
Merck (MRK) Deferred Taxes (2009 - 2026) Analysis & Trends
Merck (MRK) has 18 years of Deferred Taxes data on file, last reported at -$315.0 million in Q1 2026.
- Deferred Taxes for Q1 2026 came in at -$315.0 million, down 69.35% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.8 billion (down 30.06% YoY), and the FY2025 annual result was -$1.7 billion, down 33.79% from the prior year.
- Deferred Taxes advanced to -$315.0 million in Q1 2026 per MRK's latest filing, from -$825.0 million in the prior quarter.
- Over five years, Deferred Taxes peaked at -$51.0 million in Q1 2024 and troughed at -$931.0 million in Q4 2023.
- A 5-year average of -$394.2 million and a median of -$336.0 million in 2023 frame the typical range for Deferred Taxes.
- The sharpest annual moves came in 2022 and 2024: Deferred Taxes sank 66000.0% in 2022, then soared 81.59% in 2024.
- A 5-year view of Deferred Taxes shows it stood at -$307.0 million in 2022, then slumped by 203.26% to -$931.0 million in 2023, then soared by 33.83% to -$616.0 million in 2024, then plunged by 33.93% to -$825.0 million in 2025, then soared by 61.82% to -$315.0 million in 2026.
- Business Quant data shows MRK's Deferred Taxes at -$315.0 million in Q1 2026, -$825.0 million in Q4 2025, and -$212.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 1.48 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 159.00 Mn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 137.00 Mn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | -315.00 Mn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | -176.00 Mn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 179.00 Mn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | -12.00 Mn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 161.00 Mn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -315.00 Mn |
| Dec 31, 2025 | -825.00 Mn |
| Sep 30, 2025 | -212.00 Mn |
| Jun 30, 2025 | -448.00 Mn |
| Mar 31, 2025 | -186.00 Mn |
| Dec 31, 2024 | -616.00 Mn |
| Sep 30, 2024 | -401.00 Mn |
| Jun 30, 2024 | -181.00 Mn |
| Mar 31, 2024 | -51.00 Mn |
| Dec 31, 2023 | -931.00 Mn |
| Sep 30, 2023 | -336.00 Mn |
| Jun 30, 2023 | -355.00 Mn |
| Mar 31, 2023 | -277.00 Mn |
| Dec 31, 2022 | -307.00 Mn |
| Sep 30, 2022 | -661.00 Mn |
| Jun 30, 2022 | -262.00 Mn |
| Mar 31, 2022 | -338.00 Mn |
| Dec 31, 2021 | 159.00 Mn |
| Sep 30, 2021 | -1.00 Mn |
| Jun 30, 2021 | 11.00 Mn |